Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX07 + serplulimab
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HLX07 + serplulimab is a combination therapy consisting of two monoclonal antibodies. HLX07 is a recombinant, humanized anti-EGFR antibody developed to target the epidermal growth factor receptor (EGFR), thereby inhibiting tumor cell proliferation and survival. Serplulimab is an anti-PD-1 antibody that blocks the interaction between PD-1 and its ligands PD-L1/PD-L2, enhancing T-cell mediated immune responses against tumors. This combination has been investigated primarily for advanced or metastatic esophageal squamous cell carcinoma (ESCC), where it has shown promising antitumor activity and manageable toxicity in phase 2 clinical trials[1][4][5][8]. The regimen may also include chemotherapy agents such as cisplatin and 5-fluorouracil in some studies.
- Brand names
- HANSIZHUANG
- Other names
- HLX07 + HLX10
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on HLX07 + serplulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX07 + serplulimab.